Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Galactosemia. Core disease mechanisms, molecular and cellular pathways, in...

This report is retrieval-only and is generated directly from Asta results.

• Papers retrieved: 19
• Snippets retrieved: 20

Relevant Papers

[1] Pathophysiology and targets for treatment in hereditary galactosemia: A systematic review of animal and cellular models

• Authors: M. Haskovic, A. I. Coelho, Jörgen Bierau, Jo M. Vanoevelen, L. Steinbusch et al.
• Year: 2019
• Venue: Journal of Inherited Metabolic Disease
• URL: https://www.semanticscholar.org/paper/dea4d7499797ec21ed9d0b65b0549abfe1322ff8
• DOI: 10.1002/jimd.12202
• PMID: 31808946
• PMCID: 7317974
• Citations: 47
• Influential citations: 1
• Summary: An overview of the scattered information resulting from animal and cellular studies performed in the past decades is provided, summarising the complex pathophysiological mechanisms underlying hereditary galactosemia and providing insights on potential treatment targets.
• Evidence snippets:
• Snippet 1 (score: 0.548) > Since the first description of galactosemia in 1908 and despite decades of research, the pathophysiology is complex and not yet fully elucidated. Galactosemia is an inborn error of carbohydrate metabolism caused by deficient activity of any of the galactose metabolising enzymes. The current standard of care, a galactose‐restricted diet, fails to prevent long‐term complications. Studies in cellular and animal models in the past decades have led to an enormous progress and advancement of knowledge. Summarising current evidence in the pathophysiology underlying hereditary galactosemia may contribute to the identification of treatment targets for alternative therapies that may successfully prevent long‐term complications. A systematic review of cellular and animal studies reporting on disease complications (clinical signs and/or biochemical findings) and/or treatment targets in hereditary galactosemia was performed. PubMed/MEDLINE, EMBASE, and Web of Science were searched, 46 original articles were included. Results revealed that Gal‐1‐P is not the sole pathophysiological agent responsible for the phenotype observed in galactosemia. Other currently described contributing factors include accumulation of galactose metabolites, uridine diphosphate (UDP)‐hexose alterations and subsequent impaired glycosylation, endoplasmic reticulum (ER) stress, altered signalling pathways, and oxidative stress. galactokinase (GALK) inhibitors, UDP‐glucose pyrophosphorylase (UGP) up‐regulation, uridine supplementation, ER stress reducers, antioxidants and pharmacological chaperones have been studied, showing rescue of biochemical and/or clinical symptoms in galactosemia. Promising co‐adjuvant therapies include antioxidant therapy and UGP up‐regulation. This systematic review provides an overview of the scattered information resulting from animal and cellular studies performed in the past decades, summarising the complex pathophysiological mechanisms underlying hereditary galactosemia and providing insights on potential treatment targets.

[2] Classic galactosemia

• Authors: Haskovic Minela
• Year: 2020
• Venue: Definitions
• URL: https://www.semanticscholar.org/paper/8a8f5e491ba0a05ee08459968beda70d2631f65e
• DOI: 10.32388/nsn934
• Citations: 2
• Summary: The research presented in this dissertation will contribute to alleviate the burden on the healthcare and social systems, and to improve the psycho-social outcomes and quality of life for all galactosemia patients.
• Evidence snippets:
• Snippet 1 (score: 0.531) > The studies described in this dissertation add value to the already existing knowledge on galactosemia. > We have successfully developed an international registry for the different types of galactosemia and described the natural history of classic galactosemia in the hitherto largest cohort of patients. This is of great value for patients, their families and healthcare professionals involved in patient care. Our systematic review on the studied pathophysiological mechanisms in cellular and animal models so far will be of great value for future studies and may help reduce the use of more animals in research. In addition, we provided relevant information regarding nucleotide sugar levels in classic galactosemia that shed light on the pathophysiology underlying glycosylation abnormalities observed in this disease. > Towards our ultimate aim to develop new treatment strategies and provide the best possible care to the patients, we evaluated two treatment modalities. The non-mutation-specific mRNA-based approach holds great promise for future research, and eventually, clinical implementation. Our pilot study evaluating the therapeutic potential of arginine showed not to be beneficial in patients homozygous for p.Gln188Arg. The research presented in this dissertation will contribute to alleviate the burden on the healthcare and social systems, and to improve the psycho-social outcomes and quality of life for all galactosemia patients.

[3] Current and Future Treatments for Classic Galactosemia

• Authors: Britt Delnoy, A. I. Coelho, M. Rubio-Gozalbo
• Year: 2021
• Venue: Journal of Personalized Medicine
• URL: https://www.semanticscholar.org/paper/0560be81b4a0a635942e8493bcd3e08391ce06bd
• DOI: 10.3390/jpm11020075
• PMID: 33525536
• PMCID: 7911353
• Citations: 32
• Summary: Novel therapeutic approaches currently being explored focus on several of the pathogenic factors that have been described, aiming to restore GALT activity, influence the cascade of events and address the clinical picture.
• Evidence snippets:
• Snippet 1 (score: 0.458) > The pathogenic mechanisms underlying the acute and long-term organ-specific complications of classic galactosemia are complex and remain to be fully elucidated. Currently described contributing factors include accumulation of galactose metabolites (galactitol, galactonate and Gal-1-P) [2,[19][20][21][22][23][24][25][26][27][28][29][30], uridine diphosphate (UDP)-hexose alterations and impaired glycosylation [21,25,[31][32][33][34][35][36], endoplasmic reticulum (ER) stress with subsequent unfolded protein response (UPR), induction and alteration of signaling pathways [2][3][4][37][38][39][40][41][42], and oxidative stress [4,29,43,44] (Figure 1). > In recent years, a number of animal models (mouse, fruit fly, zebrafish, rat) [24,29,45,46] of classic galactosemia have been developed that mimic, at least partly, the biochemical and clinical phenotypes and complement the cellular models, allowing us to advance our comprehension of the complex playing field of the metabolism of galactose. We have learned that there is different expression of the Leloir pathway components and alternative galactose disposal routes in the different tissues, that combined with specific tissue demands, epigenetic and environmental factors, urge to revisit our understanding. GALT activity levels in affected organs (brain, ovaries) do not seem to differ from the activity levels in organs not affected in classic galactosemia and distinct organ-specific levels of GALT activity have been found [19]. This is reflected in the tissue related differences in relative levels of galactose metabolites (galactitol, galactose and Gal-1-P) in the rat galactosemia model [45], as well as in the nucleotide sugar profiles variation through development and in the different tissues in the zebrafish galactosemia model [31].

[4] A case report of classic galactosemia with a GALT gene variant and a literature review

• Authors: Yong-cai Wang, L. Lan, Xia Yang, Juan Xiao, Hai Liu et al.
• Year: 2024
• Venue: BMC Pediatrics
• URL: https://www.semanticscholar.org/paper/9acb35750148af54732952ea2d8db4132da2b5ba
• DOI: 10.1186/s12887-024-04769-0
• PMID: 38778342
• PMCID: 11110268
• Citations: 5
• Summary: Applications of whole-exome sequencing to detect the two variants can improve the detection and early diagnosis of classical galactosemia and, more specifically, may identify individuals who are compound heterozygous with variants in the GALT gene.
• Evidence snippets:
• Snippet 1 (score: 0.441) > Ultimately, Glu-1-P enters the glycolytic pathway. > The alternative pathway of galactose metabolism is particularly active when there are deficiencies in Leloir pathway-associated enzymes, which can lead to the accumulation of galactose and other abnormal metabolites in the body, affecting the liver, kidneys, eyes, and brain Fig. 1 Represents the standard Leloir pathway and can be fatal.Due to the toxic effects of galactose metabolites, survivors may develop various long-term complications, such as cataracts, abnormal neurological development, speech impairment, growth restriction, and premature ovarian failure [10,11]. > Blood tandem mass spectrometry screening for galactosemia is not routinely performed in China, while conventional laboratory tests make it challenging to diagnose the disease.In many countries, including those following international guidelines, the enzymatic assay, one of the recommended techniques, is no longer commonly performed and has been largely replaced by the sequencing of the GALT gene.However, in China, genetic sequencing is the primary method for diagnosing certain conditions, but it is often outsourced to third-party institutions, resulting in a long wait time for results.Galactosemia is a rare condition, and clinicians may not always be aware of it, which can result in misdiagnosis or missed diagnosis, as was the case presented in this report.There are no specific drugs for galactosemia treatment.Immediate dietary galactose restriction is required to reverse the acute postnatal symptoms of classic galactosemia. > The prevalence of classical galactosemia among populations of different ethnic backgrounds varies.Its prevalence is much higher in Western populations compared to Asian populations, with prevalence rates of 1:40,000∼1:60,000 in Europe, 1:50,000 in the United States, 1:23,500-1:44,000 in the United Kingdom, 1:42,000 in Lithuania, 1:100,000 in Japan, 1:400,000 in Taiwan, China [12], 1:50,000 in Shenzhen, China 1:50,000, and 1:759,428 in Zhejiang, China 1:759,428 [13].The disease is less reported in China.

[5] Whole-body galactose oxidation as a robust functional assay to assess the efficacy of gene-based therapies in a mouse model of Galactosemia

• Authors: B. Balakrishnan, Xinhua Yan, Marshall D McCue, Olivia Bellagamba, A. Guo et al.
• Year: 2024
• Venue: Molecular Therapy. Methods & Clinical Development
• URL: https://www.semanticscholar.org/paper/15caf17098ca72c5d901270d7460d4e09170eb25
• DOI: 10.1016/j.omtm.2024.101191
• PMID: 38352271
• PMCID: 10863324
• Citations: 6
• Summary: It is established that whole-body galactose oxidation (WBGO) as a robust, noninvasive, and specific method to assess the in vivo pharmacokinetic and pharmacodynamic parameters of two experimental gene-based therapies that aimed to restore GALT activity in a mouse model of galactosemia.
• Evidence snippets:
• Snippet 1 (score: 0.430) > Recent advances in molecular therapeutics and gene-based vaccines have paved the way for new treatment modalities for monogenic diseases such as phenylketonuria and CG. Among these modalities, gene replacement therapies and mRNA-based therapies are gaining popularity because, if successful, these modalities will address the root cause of the diseases-the absence of functional gene productsthus making them attractive and rational choices. Although efficient vectors and nanoparticles have been developed to deliver the cDNA and mRNA, respectively, to the disease-relevant organs, the in situ pharmacokinetics (PK) and pharmacodynamics (PD) assessments for the specific modality could be challenging clinically if the organs of interest are inaccessible for repeated sampling. Consequently, surrogate disease-relevant biomarkers could prove useful for part of the portfolio for the evaluation of effectiveness of the treatments under these circumstances. Ideally, the desired biomarkers are those directly implicated in the pathogenic mechanisms of the diseases so that their changes can truly reflect the change in disease states and phenotypes. However, the underlying pathophysiological mechanisms of many diseases are often not fully elucidated, which further complicates the identification of disease-relevant biomarkers for the evaluation of therapeutic efficacy. > In this study, we tested the hypothesis that whole-body galactose oxidation can be used as a noninvasive, robust, accurate, and functional biomarker for testing the effectiveness of gene-based therapies for CG. 2][3][4][5] Galactosemia patients suffer from a host of neurological complications such as ataxia, and in females, POI. 12,32,33 For decades, diagnosis of the disease relied on the detection of the abnormal accumulation of galactose metabolites such as RBC gal-1P, as well as the absence of RBC GALT activity. 34 This protocol works well for diagnosis because normal RBCs have detectable GALT expression. 35,36

[6] Novel mRNA-Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia.

• Authors: B. Balakrishnan, D. An, Vi Nguyen, Christine DeAntonis, P. Martini et al.
• Year: 2020
• Venue: Molecular therapy : the journal of the American Society of Gene Therapy
• URL: https://www.semanticscholar.org/paper/07c8805b07f790a3c40921e0fa28d08f11b6ed4d
• DOI: 10.1016/j.ymthe.2019.09.018
• PMID: 31604675
• Citations: 52
• Influential citations: 4
• Summary: This study tested whether restoration of hepatic GALT activity alone could decrease galactose-1 phosphate (gal-1P) and plasma GalT-deficient mice in the mouse model and found that repeated dosing reduced plasmaGalactose by 60% or more throughout all four doses.
• Evidence snippets:
• Snippet 1 (score: 0.426) > It has been more than a century since classic galactosemia, an inborn error of metabolism (IEM) with an incidence of 1 in 40,000 live births, was first documented, 31 and over four decades since its biochemical basis elucidated. 1,32 Despite the life-saving dietary management during the neonatal period, the continued lack of safe and effective therapies for the long-term debilitating complications has taken a heavy toll in the quality of life of over 2,000 patients worldwide and their caregivers. [33][34][35][36][37][38][39][40] Traditional therapeutic strategies for IEMs focused on ERT and substrate reduction therapy. While ERT enjoys some successes in lysosomal storage diseases, 41 the CNS pathology associated with the diseases remain a challenge because of the inability of the enzymes to cross the blood-brain barrier (BBB). 42 Therefore, the efficacy of ERT in treating the neurological complications of galactosemia could be limited. Substrate reduction therapy through galactose restriction has been instrumental in averting the lethality during the neonatal period of the affected patients, but the galactose-restricted diet alone is insufficient to prevent the long-term complications. Other emerging experimental therapeutic approaches for galactosemia include the targeting of galactokinase 43,44 and aldose reductase, 45 as well as endoplasmic reticulum stress 46,47 by small molecule inhibitors, but none of them have reached the stage for clinical trials at this moment. > Although the environmental and molecular mechanisms for the longterm complications associated with classic galactosemia have not been fully delineated, none will debate that the disease is caused by deleterious mutations in the GALT genes, which result in the complete absence of cellular GALT enzyme activity. In this study, we pursued a nucleic acid-based therapeutic strategy, where we delivered human GALT (hGALT) mRNA into the liver of a GalT-deficient mouse at which the hGALT mRNA will be translated and form functional GALT enzyme. We hypothesized that upon hepatic hGALT gene expression, the liver will act as a "sink" to metabolize all the excess galactose

[7] Experimental Galactose-1-Phosphate Uridylyltransferase (GALT) mRNA Therapy Improves Motor-Related Phenotypes in a Mouse Model of Classic Galactosemia—A Pilot Study

• Authors: Olivia Bellagamba, A. Guo, Xinhua Yan, Joe Sarkis, B. Balakrishnan et al.
• Year: 2025
• Venue: Biomedicines
• URL: https://www.semanticscholar.org/paper/a4c5a00536a991fa9cfba61ae486e35fac705354
• DOI: 10.3390/biomedicines13122848
• PMID: 41462863
• PMCID: 12731057
• Summary: A biweekly dosing regimen at 2mg/kg for 2 months could improve the motor performance of the animals in Rotarod and Composite Phenotype Scoring tests and showed that administration of GALT mRNA in the mutant mice restored whole-body galactose oxidation (WBGO), a functional biomarker.
• Evidence snippets:
• Snippet 1 (score: 0.423) > Except for the ovarian phenotype, there is considerable variability among other long-term complications. To-date, there is no effective treatment available to prevent or alleviate any of the above-mentioned long-term complications. Yet, regardless of the pathophysiological mechanisms, no one will argue that the root cause of the disease is the absence of GALT enzyme activity in patient cells. Therefore, therapeutic strategies that aim to restore GALT enzyme activity in the patients represent a rational and direct approach to address the unmet medical needs of the patients. Among them, experimental GALT mRNA therapy has emerged as a promising modality [17][18][19]. Indeed, we demonstrated significant efficacy of GALT mRNA in normalizing the disease-relevant biomarkers and restoring whole-body galactose oxidation in a mouse model of classic galactosemia. > Figure 1. The Leloir pathway of galactose metabolism and the proposed pathobiology of galactose-1phosphate uridylyltransferase (GALT) deficiency. Galactose, absorbed via diet or produced endogenously in a cell, is phosphorylated to form galactose-1-phosphate (Gal-1P). In the absence of GALT, the build-up of Gal-1P is thought to induce abnormal integrated response (ISR), which plays a role in the pathophysiology of the disease. Administration of GALT mRNA (green arrow) is expected to restore expression of GALT enzyme, thus effectively eliminating the Gal-1P accumulation. > In this short-term study, we expanded our preclinical proof-of-concept studies to include motor impairment, a disease-relevant phenotype. By doing so, we aimed to address the following three questions: > 1. > Will experimental GALT mRNA therapy improve motor-related phenotypes in a mouse model of classic galactosemia? 2. > Will the improvement, if any, of motor-related phenotypes seen in the treated animals be sustained after the cessation of the experimental GALT mRNA treatment?

[8] Clinical metabolomics in type 2 diabetes mellitus: from pathogenesis to biomarkers

• Authors: Chuanxin Liu, Hetao Chen, Yujin Ma, Lei Zhang, Lulu Chen et al.
• Year: 2025
• Venue: Frontiers in Endocrinology
• URL: https://www.semanticscholar.org/paper/36f8d26a208b7b96763df2e9aa3211e440031c0e
• DOI: 10.3389/fendo.2025.1501305
• PMID: 40070584
• PMCID: 11893406
• Citations: 10
• Summary: The results facilitate understanding the pathophysiology and mechanism of type 2 diabetes mellitus and supports research in accurate diagnosis, risk prediction, curative effect, distinct stages, and prognosis judgment of T2DM.
• Evidence snippets:
• Snippet 1 (score: 0.422) > The metabolome is sensitive to a variety of genetic and environmental stimuli and susceptible to genetic, environmental, and gut microbiome pressures, so subtle differences between individuals can lead to large perturbations in metabolite concentrations and fluxes (15, 24). At present, cystatin C has become an ideal endogenous marker for evaluating glomerular filtration function because it is not affected by sex, age or muscle mass (25). In addition, more and more evidence shows that serum CysC is involved in the pathological process of vascular remodeling and neovascularization, which is closely related to the occurrence and development of diabetic microangiopathy (26). > Eighty-four papers were included in this review and obtained through database searches, namely, PubMed, Cochrane Library, China national knowledge internet(CNKI), General Purpose, and VIP Database. The keywords for the searches were "metabolomics" and "type 2 diabetes mellitus" and its complications. The papers were incorporated by reading and summarizing the literature according to the classification standards (27). The profound analysis of clinical differential metabolites identified in type 2 diabetes and its complications were conducted concerning composition, frequency of category, sample type, and pathways to explore the pathological mechanism of type 2 diabetes and its complications to provide a systematic basis for clinical diagnosis, risk stratification, comprehending disease progression, prognosis assessment, and drug efficacy. Our goal is to apply metabolomics to clinical diagnostic biomarkers, metabolic mechanisms, and prognostic observations, and early diagnosis can be made through metabolites to avoid progression to more serious complications.
• Snippet 2 (score: 0.402) > T2DM is a chronic disease characterized by two primary pathophysiological mechanisms: ① a reduction in the mass and function of pancreatic b cells, ranging from 20% to 65%, which leads to impaired insulin secretion; ② insulin resistance, where cells in muscles, fat, and liver tissues fail to respond adequately to insulin (9). Consequently, higher levels of insulin are required to maintain normal blood glucose concentrations by inhibiting hepatic glucose production and promoting glucose uptake in muscle and adipose tissues. Prolonged exposure to elevated levels of circulating insulin leads to the development of insulin resistance in peripheral tissues, and over time, the pancreas fails to produce sufficient insulin to overcome this cellular resistance (10). However, due to the long latent period and absence of obvious symptoms initially, reversing T2DM with drug intervention is difficult after the symptoms are exposed or clinically confirmed in light of clear diagnostic criteria. According to the literature, the pathogenesis and process of metabolic syndromes such as diabetes and its complications are mainly reflected in the metabolite network, and the mechanism changes at the gene level are also found in the network. Studies have shown that some related metabolites in patients with diabetes have changed before the occurrence of obvious organic damage (11). Therefore, it is necessary to scientifically prevent T2DM in the early stages of disease onset. Fortunately, clinical metabolomics were employed to understand the progression pathologies of T2DM and its corresponding complications in detail (12). Studies have demonstrated that metabolomic analysis enables the exploration of metabolic disorders associated with T2DM, thereby deepening our understanding of disease progression (13,14). This approach has the potential to facilitate novel clinical diagnoses and the development of effective treatment strategies. Moreover, identifying specific metabolites may provide promising biomarkers for the early prediction, prevention, and management of hyperglycemia and its complications (15). In recent years, excellent progress has been made in the study of T2DM and its complications through High throughput sequencing method, i.e., a discipline specifically focused on metabolic small molecules. > Clinical metabolomics is a type of systems biology research closely linked to phenotype.

[9] Changes in Serum Proteomic Profiles at Different Stages of Pregnancy Toxemia in Goats

• Authors: M. Uzti̇mür, C. N. Ünal, Gurler Akpinar
• Year: 2025
• Venue: Journal of Veterinary Internal Medicine
• URL: https://www.semanticscholar.org/paper/4b9c488b5dbd65d7b26fd2ad9aed70e8c4b59942
• DOI: 10.1111/jvim.70139
• PMID: 40492724
• PMCID: 12150350
• Summary: Understanding the serum proteome profiles of goats with pregnancy toxemia might help identify the proteomes and pathways responsible for the development of this disease and improve diagnosis and treatment.
• Evidence snippets:
• Snippet 1 (score: 0.419) > The pathophysiology and progression of this disease are not fully understood. > Traditional biomedical research has focused on the analysis of single genes, proteins, metabolites, or metabolic pathways in diseases. This molecular reductionist approach is based on the assumption that identifying genetic variations and molecular components will lead to new treatments for diseases [13][14][15][16]. However, many diseases are complex and multifactorial, and in order to determine the phenotype of such diseases, it is necessary to understand the changes that occur in more than one gene, pathway, protein, or metabolite at the cellular, tissue, and organismal levels [17][18][19]. Therefore, in recent years, proteomics, as one field of multi-omics technologies, has helped in evaluating the complex pathogenetic mechanisms of different diseases from a broad perspective and has made substantial contributions [20,21]. In veterinary medicine, proteomic analysis of metabolic diseases such as ketosis [16], hypocalcemia [22], and fatty liver [23] in dairy cows has contributed valuable insights for the definition of new pathophysiological pathways and new diagnosis and treatment protocols for these diseases. The proteomic approach can contribute importantly to a broad and detailed understanding of the changes that occur at the organismal level associated with the increase in BHBA concentration in goats with pregnancy toxemia. Our aim was to evaluate the serum protein profiles of goats with SPT or CPT using proteomic techniques to determine the proteomic profiles of these animals and to identify the relevant pathophysiological mechanisms.

[10] Functional analysis of GALT variants found in classic galactosemia patients using a novel cell‐free translation method

• Authors: D. Canson, C. Silao, S. Caoili
• Year: 2019
• Venue: JIMD Reports
• URL: https://www.semanticscholar.org/paper/04704668a3819e473c38d0d8357badc16fc897eb
• DOI: 10.1002/jmd2.12037
• PMID: 31392114
• PMCID: 6606980
• Citations: 2
• Influential citations: 1
• Summary: Biochemical and computational data support the classification of p.Leu116Pro and p.Met178Arg variants as pathogenic and the protein expression method developed has utility for future studies of GALT variants.
• Evidence snippets:
• Snippet 1 (score: 0.404) > Classic galactosemia is an autosomal recessive disorder caused by deleterious variants in the galactose‐1‐phosphate uridylyltransferase (GALT) gene. GALT enzyme deficiency leads to an increase in the levels of galactose and its metabolites in the blood causing neurodevelopmental and other clinical complications in affected individuals. Two GALT variants NM_000155.3:c.347T>C (p.Leu116Pro) and NM_000155.3:c.533T>G (p.Met178Arg) were previously detected in Filipino patients. Here, we determine their functional effects on the GALT enzyme through in silico analysis and a novel experimental approach using a HeLa‐based cell‐free protein expression system. Enzyme activity was not detected for the p.Leu116Pro protein variant, while only 4.5% of wild‐type activity was detected for the p.Met178Arg protein variant. Computational analysis of the variants revealed destabilizing structural effects and suggested protein misfolding as the potential mechanism of enzymological impairment. Biochemical and computational data support the classification of p.Leu116Pro and p.Met178Arg variants as pathogenic. Moreover, the protein expression method developed has utility for future studies of GALT variants.

[11] Organoids in gastrointestinal diseases: from bench to clinic

• Authors: Qinying Wang, Fanying Guo, Qinyuan Zhang, Tingting Hu, Yutao Jin et al.
• Year: 2024
• Venue: MedComm
• URL: https://www.semanticscholar.org/paper/9b8880d8b9d45670da950197d7e353794f51d09e
• DOI: 10.1002/mco2.574
• PMID: 38948115
• PMCID: 11214594
• Citations: 12
• Summary: A comprehensive and systematical depiction of organoids models is drawn, providing a novel insight into the utilization of organoids models from bench to clinic and clinical adhibition.
• Evidence snippets:
• Snippet 1 (score: 0.404) > Organoids models offer a robust platform for investigating the potential mechanisms of GI diseases and evaluating potential therapeutic interventions.By culturing organoids derived from patients' tissues or stem cells, researchers can delve into disease-specific cellular and molecular pathways, encompassing aberrant cell signaling, perturbed immune responses, and dysfunctional metabolic processes.These disease-specific phenotypes enable the study of disease progression, screening of prospective therapeutics, as well as identification of novel drug targets and mechanisms of action for GI diseases in a clinically relevant context.

[12] New therapeutic targets in rare genetic skeletal diseases

• Authors: M. Briggs, Peter A. Bell, M. Wright, K. A. Pirog
• Year: 2015
• Venue: Expert Opinion on Orphan Drugs
• URL: https://www.semanticscholar.org/paper/1363107f71ae6d2d60abca471cddf3da5d13644b
• DOI: 10.1517/21678707.2015.1083853
• PMID: 26635999
• PMCID: 4643203
• Citations: 37
• Influential citations: 1
• Summary: An overview of disease mechanisms that are shared amongst groups of different GSDs and potential therapeutic approaches that are under investigation are described to generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
• Evidence snippets:
• Snippet 1 (score: 0.402) > proteins of the cartilage ECM such as type II collagen [50]. However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e. chondrocyte) to the abnormal extracellular environment is also important for disease progression as illustrated by several GSDs discussed in this review. > It is important that 'omics'-based approaches and technologies are systematically applied to the study of rare GSDs so that definitive reference profiles and disease signatures are generated for each phenotype. These can then be used in a Systems Biology approach to identify both common and dissimilar pathological signatures and disease mechanisms. This approach is entirely dependent upon relevant in vitro and in vivo models (and also novel 'disease-mechanism phenocopies' [107]) for testing new diagnostic and prognostic tools and for determining the molecular mechanisms that underpin the pathophysiology so that effective therapeutic treatments can be developed and validated. This approach will eventually lead to personalized treatments and care strategies centred on shared disease mechanisms with the use of relevant biomarkers to monitor the efficacy of treatment and disease progression. > It is vital that all relevant stakeholders are involved from the outset in defining the appropriate outcomes of any potential therapeutic regime. The perceptions of a successful therapy can differ widely between the clinical academic community and the relevant patient-support groups and it is vital that there is engagement on all these issues. > In summary, the identification of causative genes and mutations for GSDs over the last 20 years, coupled with the generation and in-depth analysis of a plethora of relevant cell and mouse models, has derived new knowledge on disease mechanisms and suggested potential therapeutic targets. The fast-evolving hypothesis that clinically disparate diseases can share common disease mechanisms is a powerful concept that will generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.

[13] Lactate metabolism and lactylation in kidney diseases: insights into mechanisms and therapeutic opportunities

• Authors: Yuhua Cheng, Linjuan Guo
• Year: 2025
• Venue: Renal Failure
• URL: https://www.semanticscholar.org/paper/6208b88884af543f7c97d2e70ed6b727dcfb4f58
• DOI: 10.1080/0886022X.2025.2469746
• PMID: 40012230
• PMCID: 11869332
• Citations: 9
• Summary: A review examines the role of lactate esters, especially lactylation, in kidney diseases, with a focus on their regulatory mechanisms and potential as therapeutic targets.
• Evidence snippets:
• Snippet 1 (score: 0.395) > Lactate metabolism and its post-translational modifications, particularly lactylation, play critical roles in the pathophysiology of various kidney diseases, including AKI, DKD, and ccRCC (Figure 1). The kidney's ability to metabolize lactate is crucial for maintaining renal function under normal conditions. However, in pathological states, impaired lactate metabolism leads to its accumulation, exacerbating renal dysfunction and disease progression. For more details on lactate metabolism and kidney diseases, refer to previous reviews [2,3,25]. > Lactylation influences gene transcription, protein function, and cellular metabolism, contributing to inflammatory responses, mitochondrial dysfunction, and tumor progression. > Understanding the mechanisms of lactate metabolism and lactylation in kidney diseases opens new avenues for therapeutic interventions. Targeting these metabolic pathways could mitigate renal injury and improve patient outcomes. Future research should focus on elucidating the specific pathways and molecular targets affected by lactate and lactylation and developing inhibitors to modulate these processes. Clinical trials are necessary to validate the efficacy and safety of these therapies. Overall, the lactate-lactylation axis is a promising target for novel therapeutic strategies aimed at treating kidney diseases and improving renal health.

[14] Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight

• Authors: F. Iheagwam, A. J. Joseph, E. D. Adedoyin, Olawumi Toyin Iheagwam, Samuel Akpoyowvare Ejoh
• Year: 2025
• Venue: Pathophysiology
• URL: https://www.semanticscholar.org/paper/dbf8042761c1a5fc50f8cd894cc498505abac7cb
• DOI: 10.3390/pathophysiology32010009
• PMID: 39982365
• PMCID: 12077258
• Citations: 23
• Summary: This review aims to elucidate the complex link between mitochondrial dysfunction and diabetes, covering the spectrum of diabetes types, the role of mitochondria in insulin resistance, highlighting pathophysiological mechanisms, mitochondrial DNA damage, and altered mitochondrial biogenesis and dynamics.
• Evidence snippets:
• Snippet 1 (score: 0.394) > The landscape of DM research is continuously evolving, with emerging technologies and approaches offering new insights into the pathophysiology of the disease and potential therapeutic targets. Advancements in omics technologies, encompassing genomes, transcriptomics, proteomics, and metabolomics, have transformed the molecular mechanisms underlying DM [134]. High-throughput sequencing techniques enable comprehensive analysis of genetic variants, gene expression profiles, protein abundance, and metabolite levels associated with DM and its complications [135]. Single-cell omics approaches provide unprecedented resolution and granularity, allowing researchers to dissect cellular heterogeneity and identify novel cell types, subpopulations, and signalling pathways involved in DM pathogenesis. Integrating multi-omics data sets offers a systems-level perspective of DM, unravelling complex networks of molecular interactions and regulatory circuits underlying disease progression [136]. > In addition to omics technologies, advances in imaging modalities, such as MRI, PET, and optical imaging, enable non-invasive visualisation and quantification of metabolic, functional, and structural changes. Molecular imaging probes targeting specific biomarkers and metabolic pathways provide valuable insights into disease mechanisms and treatment responses in preclinical and clinical settings [85]. Despite significant progress in DM research, numerous unanswered questions and knowledge gaps persist, hindering the ability to develop effective prevention and treatment strategies. Key areas requiring further investigation include the role of epigenetics, environmental factors, and the microbiome in DM susceptibility and progression. Moreover, the interaction between environmental cues and genetic predisposition remains incompletely understood, highlighting the need for comprehensive multi-omics studies and large-scale epidemiological analyses to identify gene-environment interactions and modifiable risk factors for DM [137]. Furthermore, the heterogeneity of DM phenotypes and clinical outcomes poses a challenge for personalised medicine approaches, necessitating robust biomarkers and predictive models to stratify patients based on disease subtypes, prognosis, and treatment response [138].

[15] Language production and working memory in classic galactosemia from a cognitive neuroscience perspective: future research directions

• Authors: I. Timmers, J. Hurk, F. Di Salle, M. Rubio‐Gozalbo, B. Jansma
• Year: 2011
• Venue: Journal of Inherited Metabolic Disease
• URL: https://www.semanticscholar.org/paper/e4f6397928038f7f2c30b1b2aae8fde3a3f548c8
• DOI: 10.1007/s10545-010-9266-4
• PMID: 21290187
• PMCID: 3063545
• Citations: 25
• Summary: Cognitive theories on language production and methods used in cognitive neuroscience are briefly introduced and the possibilities of applying them in experimental paradigms to investigate languageproduction and verbal memory in galactosemia are reviewed.
• Evidence snippets:
• Snippet 1 (score: 0.392) > might affect language function. A target method of choice to investigate differences in such information flow within neural circuits, such as the arcuate fasciculus, in galactosemia patients versus healthy controls would be functional connectivity analysis. > Recently, it has been suggested that epigenetic factors may be involved in the pathology of galactosemia. Coman et al. (2010) studied gene expression profiles of four galactosemia patients. They identified several up-or downregulations in gene expressions in these patients. Genes involved in cell signaling pathways, such as the mitogen-activated protein kinase (MAPK) signaling and the calcium signaling pathway, both implicated in neural signaling processes, showed different expression patterns. The most dysregulated gene was Septin 4, of which the expression was decreased 85-fold. Septins are proteins that are involved in a large number of cellular functions, such as membrane dynamics, cytokinesis, vesicle trafficking, exocytosis, and apoptosis (Cao et al. 2009;Haller et al. 2005). Septin 4 (or SEPT4) proteins have been implicated in neurodegenerative diseases, such as Alzheimer's disease or Parkinson's disease. It is expressed in all human tissue, but shows an high expression in the brain (Haller et al. 2005). Further studies will be necessary to elucidate whether these genes are relevant for the origin of the chronic complications. One of the possibilities might be to use ultra high field imaging. With this method, the detection of proteins by producing specifically tailored contrast mechanisms, e.g. by the use of immunoconjugated magnetic nanoparticles (Hilger et al. 2007), might become possible in the future. This in turn might permit to quantify the density of specific substances, among which Septin 4, which can be linked to specific brain regions of functional interest, such as memory or language. > It would be intriguing to examine whether genes encoding for cognitive functions are differentially expressed in galactosemia. One such gene is the FOXP2 transcription factor gene, which has been implicated in speech and language disabilities (Enard et al. 2002;Fisher and Scharff 2009). Such a research would provide another missing link: the link between the genes and

[16] Early postnatal alterations in follicular stress response and survival in a mouse model of Classic Galactosemia

• Authors: Synneva Hagen-Lillevik, Joshua Johnson, K. Lai
• Year: 2022
• Venue: Journal of Ovarian Research
• URL: https://www.semanticscholar.org/paper/dee9a5865f36dbe98e9ecab78d632b0ea132c4ac
• DOI: 10.1186/s13048-022-01049-2
• PMID: 36414970
• PMCID: 9682695
• Citations: 8
• Summary: The findings indicate that abnormal Integrated Stress Response in the Classic Galactosemia model ovary results in accelerated primordial follicle growth activation, sometimes referred to as “burnout,” which helps clarify when/how the primary ovarian insufficiency phenotype arises under galactosemic conditions.
• Evidence snippets:
• Snippet 1 (score: 0.391) > Primary ovarian insufficiency is characterized by accelerated loss of primordial follicles, which results in ovarian failure and concomitant menopause before age 40. About 1–3% of females in the general population are diagnosed with POI; however, greater than 80% of females with the inherited disease Classic Galactosemia will develop POI. Classic Galactosemia is caused by mutations in the GALT gene encoding the enzyme galactose-1 phosphate uridylyltransferase. While dietary restriction of galactose is lifesaving in the neonatal period, the development of complications including primary ovarian insufficiency is not mitigated. Additionally, the pattern(s) of follicle loss have not been completely characterized. The chronic accumulation of aberrant metabolites such as galactose-1-phosphate and galactitol are suspected culprits in the development of the sequelae, yet the mechanisms remain elusive. Our group uses a GalT gene-trapped mouse model to study the pathophysiology of primary ovarian insufficiency in Classic Galactosemia. We recently showed that differences in the Integrated Stress Response pathway occur in mutant ovaries that likely contribute to their primary ovarian insufficiency phenotype. Using immunofluorescent staining of histological sections of ovaries at progressive ages, we saw evidence of altered Integrated Stress Response activity in granulosa cells and primordial oocytes consistent with accelerated primordial follicle growth activation, aberrant DNA damage and/or repair, and increased cellular stress/death. Overall, our findings indicate that abnormal Integrated Stress Response in the Classic Galactosemia model ovary results in accelerated primordial follicle growth activation, sometimes referred to as “burnout.” These aberrant early events help further clarify when/how the primary ovarian insufficiency phenotype arises under galactosemic conditions.

[17] Novel Approaches to Studying SLC13A5 Disease

• Authors: Adriana S. Beltran
• Year: 2024
• Venue: Metabolites
• URL: https://www.semanticscholar.org/paper/8469c534cd81d96f84b61e2d963dead12088feb7
• DOI: 10.3390/metabo14020084
• PMID: 38392976
• PMCID: 10890222
• Citations: 2
• Summary: Current technologies for generating patient-specific induced pluripotent stem cells (iPSCs) and their inherent advantages and limitations are discussed, followed by a summary of the methods for differentiating iPSCs into neurons, hepatocytes, and organoids.
• Evidence snippets:
• Snippet 1 (score: 0.386) > The precise pathophysiology underlying how SLC13A5 loss-of-function results in epilepsy refractory to treatment is a subject of open and ongoing research. Several hypotheses suggest SLC13A5 alters metabolic pathways, leading to neuronal dysfunction. Conversely, therapeutic inhibition of NaCT in the liver is a target to improve metabolic diseases, including non-alcoholic fatty liver disease, obesity, and insulin resistance. Thus, functionally accurate modeling and characterization of the mechanisms involved in citrate transport disruption are critical for understanding its role in human disease. > IPSC-derived cellular systems are a powerful tool for modeling rare human genetic diseases, such as SLC13A5 (Figure 5). IPSCs derived from patients containing the genetic information of the disease can overcome the limitations of animal models, providing access to relevant human cell types that recapitulate the disease phenotype. For instance, patient-derived iPSCs differentiated into neurons or hepatocytes can be used to investigate molecular and cellular mechanisms, including citrate transport and accumulation, energy metabolism, oxidative stress, and other cellular processes. They can also be used to define the spectrum of the disease and how different mutations might lead to various disease severities, screen for potential therapeutic compounds that can restore the transporter function or ameliorate the symptoms, and enable personalized medicine approaches that can tailor treatments to individual patients based on their genetic background and disease severity. > transport disruption are critical for understanding its role in human disease. > IPSC-derived cellular systems are a powerful tool for modeling rare human genetic diseases, such as SLC13A5 (Figure 5). IPSCs derived from patients containing the genetic information of the disease can overcome the limitations of animal models, providing access to relevant human cell types that recapitulate the disease phenotype. For instance, patient-derived iPSCs differentiated into neurons or hepatocytes can be used to investigate molecular and cellular mechanisms, including citrate transport and accumulation, energy metabolism, oxidative stress, and other cellular processes.

[18] mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR node

• Authors: Laura Mantoan Ritter, N. M. P. Annear, E. Baple, Leila Y. Ben-Chaabane, Istvan Bodi et al.
• Year: 2025
• Venue: Orphanet Journal of Rare Diseases
• URL: https://www.semanticscholar.org/paper/f30b2504a3b3bbb7264847da72e690aebd2919d7
• DOI: 10.1186/s13023-025-03740-1
• PMID: 40426219
• PMCID: 12107773
• Citations: 5
• Summary: How mTOR pathway diseases provide an opportunity to coordinate basic and translational disease research across the group, together with industry, medical research foundations, charities and patient groups, by pooling expertise and driving progress to benefit patients is expound.
• Evidence snippets:
• Snippet 1 (score: 0.380) > Mechanistic target of rapamycin (mTOR) is a highly conserved serine/threonine kinase that regulates key cellular processes including cell growth, autophagy and metabolism. Hyperactivation of the mTOR pathway causes a group of rare and ultrarare genetic diseases. mTOR pathway diseases have diverse clinical manifestations that are managed by distinct medical disciplines but share a common underlying molecular basis. There is a now a deep understanding of the molecular underpinning that regulates the mTOR pathway but effective treatments for most mTOR pathway diseases are lacking. Translating scientific knowledge into clinical applications to benefit the unmet clinical needs of patients is a major challenge common to many rare diseases. In this article we expound how mTOR pathway diseases provide an opportunity to coordinate basic and translational disease research across the group, together with industry, medical research foundations, charities and patient groups, by pooling expertise and driving progress to benefit patients. We outline the germline and somatic mutations in the mTOR pathway that cause rare diseases and summarise the prevalence, genetic basis, clinical manifestations, pathophysiology and current treatments for each disease in this group. We describe the challenges and opportunities for progress in elucidating the underlying mechanisms, improving diagnosis and prognosis, as well as the development and approval of new therapies for mTOR pathway diseases. We illustrate the crucial role of patient public involvement and engagement in rare disease and mTOR pathway disease research. Finally, we explain how the mTOR Pathway Diseases node, part of the Research Disease Research UK Platform, will address these challenges to improve the understanding, diagnosis and treatment of mTOR pathway diseases.

[19] Novel variants in KAT6B spectrum of disorders expand our knowledge of clinical manifestations and molecular mechanisms

• Authors: M. Yabumoto, Jessica Kianmahd, Meghna Singh, Maria F. Palafox, Angela Wei et al.
• Year: 2021
• Venue: Molecular Genetics & Genomic Medicine
• URL: https://www.semanticscholar.org/paper/3a47a1b1208ba7420900b090d3d7d712ed391719
• DOI: 10.1002/mgg3.1809
• PMID: 34519438
• PMCID: 8580094
• Citations: 12
• Influential citations: 2
• Summary: A range of features previously described for KAT6B‐related syndromes are identified, including concern for keratoconus, sensitivity to light or noise, recurring infections, and fractures in greater numbers than previously reported.
• Evidence snippets:
• Snippet 1 (score: 0.380) > Finally, as gene-centric models of disease have started to take hold, understanding the underlying functional mechanisms that are affected can help us elucidate the effect on molecular and cellular phenotypes that are regulated by KAT6B (Klein et al., 2019;Sheikh et al., 2012). We developed a model of KAT6B truncating variants in a human cell line to explore how these variants result in differential regulation of key transcripts. These types of approaches have been performed in a high throughput manner for tumor suppressor genes like BRCA1 (Findlay et al., 2018) and TP53 (Kotler et al., 2018) and can help identify key pathways that are dysregulated by KAT6B-related disorders and could be future targets for translational research. > Here, we analyze 20 clinical cases representing a KAT6B-related clinical spectrum across three domains: their genotype, phenotype, and experience with genetic counseling resources. Furthermore, we developed an in vitro model of KAT6B mutations using CRISPR technology to explore the effect of protein truncation on global transcriptional regulation. Here we demonstrate that the genes that drive core clinical phenotypes are enriched in our in vitro model system. Together, we show that our clinical observations parallel the transcriptional processes in our cell model systems which allow for a further understanding of the mechanisms underlying the KAT6Brelated clinical spectrum.

Notes

• This provider combines search_papers_by_relevance with snippet_search.
• No synthesis or second-stage model call is performed.

Disorder

• Name: Galactosemia
• Category: Genetic
• Existing deep-research providers: cyberian-codex, perplexity
• Existing evidence reference count in YAML: 12

Key Pathophysiology Nodes

• Galactose-1-phosphate accumulation
• UDP-galactose deficiency
• Galactitol toxicity
• Deep research literature mapping

Citation Inventory (for evidence mapping)

• DOI:10.1002/jcp.20820
• DOI:10.1002/jimd.12202
• DOI:10.1007/s10545-016-9993-2
• DOI:10.3389/fgene.2024.1355962
• DOI:10.3389/fpls.2020.00167
• PMID:1150052
• PMID:1561928
• PMID:1706789
• PMID:31774565
• PMID:331112
• PMID:39704415
• PMID:41083920

Galactosemia: A Comprehensive Analysis of Disease Pathophysiology

Galactosemia represents a group of rare inherited metabolic disorders that fundamentally disrupt the body's ability to process galactose, a simple sugar found in dairy products and synthesized endogenously in human tissues[2][6]. The disease encompasses four distinct types caused by deficiencies in different enzymes of the Leloir pathway, with classic galactosemia (Type I) resulting from galactose-1-phosphate uridylyltransferase (GALT) deficiency being the most severe and common form[1][2]. Despite the availability of newborn screening and early dietary intervention with galactose-restricted diets, the majority of affected patients develop progressive long-term complications affecting the central nervous system, reproductive system, and skeletal integrity, underscoring the complexity of disease mechanisms that extend far beyond simple substrate accumulation[8][14][31]. This comprehensive review examines the molecular and cellular pathophysiology of galactosemia, exploring the interconnected mechanisms that drive disease progression, the tissue-specific vulnerabilities that determine clinical manifestations, and the emerging therapeutic targets that offer promise for preventing or ameliorating these devastating complications.

Enzymatic Basis and the Leloir Pathway of Galactose Metabolism

The Leloir pathway represents the principal metabolic route for galactose metabolism in mammalian cells, comprising a carefully orchestrated series of enzymatic steps that transform dietary and endogenously produced galactose into glucose and other essential metabolic intermediates[3][13][38][39]. The pathway begins with the action of galactose mutarotase (GALM), which catalyzes the reversible interconversion between the β-D and α-D anomeric forms of galactose[38][39]. This conformational change is essential because only the α-D-galactose form serves as a substrate for the subsequent enzymatic steps[3][38]. The converted α-D-galactose then enters the second step of the pathway, where galactokinase (GALK1) phosphorylates it to galactose-1-phosphate (Gal-1-P) in an ATP-dependent reaction[3][38][39]. This phosphorylation is critical because it traps galactose within the cell, preventing its escape and allowing the metabolism to proceed[3].

The third and most crucial step of the Leloir pathway involves galactose-1-phosphate uridylyltransferase (GALT), which catalyzes a nucleotide transfer reaction that displaces galactose-1-phosphate with UDP-glucose, generating both glucose-1-phosphate and UDP-galactose[3][13][38][39]. This enzyme operates through a sophisticated two-step 'ping-pong' mechanism involving a covalent enzyme-bound uridylylated intermediate[1]. The reaction begins with the hydrolysis of the UDP-sugar substrate, resulting in a phospho-histidine bond between uridine monophosphate (UMP) and His186 (or His166 in non-human GALT) from the active site motif 'HPH'[1]. The fourth and final step employs UDP-galactose 4'-epimerase (GALE) to catalyze the reversible conversion of UDP-galactose back to UDP-glucose, regenerating the substrate necessary for continuation of the cyclic pathway[29][38][39]. The glucose-1-phosphate generated in step three can subsequently enter glycolysis through conversion to glucose-6-phosphate by phosphoglucomutase, generating ATP and pyruvate, or can be diverted toward inositol biosynthesis, underlining the metabolic centrality of this pathway[29][38].

Genetic and Molecular Basis of Galactosemia

Galactosemia is inherited in an autosomal recessive manner, requiring biallelic mutations in the affected gene for disease manifestation[2][16][38][43][45]. Over 300 disease-associated mutations have been identified in the GALT gene alone, with the vast majority being missense changes that alter amino acid composition rather than causing frameshift or nonsense mutations[1][2]. The most prevalent pathogenic variant in European populations is the missense mutation c.563A>G, which encodes the p.Gln188Arg substitution, accounting for approximately 60 percent of classic galactosemia cases[1][43]. This variant affects an active site residue that directly interacts with the phosphate and ribose moieties of the covalently attached UMP, as well as the phosphate moiety of hexose-1-phosphate[1]. The second most common variant, c.855G>T (p.Lys285Asn), is particularly prevalent in European populations where it accounts for 26 to 34 percent of galactosemia alleles[16]. This variant removes three hydrogen bonds involving helix α₆, likely destabilizing the overall protein structure[1]. The third most frequent variant, c.404C>T (p.Ser135Leu), is predominantly found in African American populations and is associated with a less severe phenotype[43].

The molecular consequences of these mutations vary considerably based on their location and structural impact[1][16]. Some variants, such as p.Gln188Arg, compromise the stability of the uridylylated intermediate and reduce GALT's ability to bind and process substrate efficiently[1]. Other variants, including p.Ser135Leu and p.Lys285Asn, function primarily as misfolding variants that reduce protein stability and increase aggregation propensity[1]. A subset of variants alter dimer interactions through disruption of critical inter-chain salt-bridges, such as p.Asp113Asn and p.His114Leu[1]. The Duarte variant (Asn314Asp or N314D) represents an allelic variant that reduces but does not eliminate enzyme activity, retaining 5 to 20 percent of normal activity, resulting in a much milder phenotype[2][6][42]. The clinical variant form of galactosemia, characterized by residual GALT activity between 1 and 10 percent, demonstrates that even modest enzyme retention can substantially ameliorate disease severity compared to the complete or near-complete deficiency seen in classic galactosemia[16][43][46].

Recent structural studies have illuminated how uridylylation and zinc binding profoundly influence the stability and aggregation tendency of human GALT protein[1]. The crystal structure of human GALT demonstrates that the covalent modification at His186 by UMP has structural effects on the enzyme that had previously been unrecognized[1]. This finding has important implications for disease-associated variants where the most common p.Gln188Arg mutation increases the rate of aggregation in the absence of zinc, likely due to its reduced ability to form the uridylylated intermediate[1]. Such structural insights provide a template for the future design of pharmacological chaperone therapies and open new concepts about the roles of metal binding and enzyme activity in protein misfolding by disease-associated mutants[1].

Accumulation of Toxic Metabolites and Primary Pathophysiological Consequences

When GALT activity is severely deficient or absent, galactose accumulates and is shunted into alternative metabolic pathways that generate toxic metabolites responsible for much of the disease pathology[3][6][11][13][31]. The first major alternative pathway converts excess galactose into galactitol through the action of aldose reductase (AR), an NADPH-dependent enzyme that normally plays a minor role in galactose metabolism but becomes hyperactive when the Leloir pathway is impaired[3][6][11][13][31]. Galactitol is particularly problematic because it is poorly metabolized and accumulates within cells, generating osmotic stress that leads to cell swelling, water influx, and cellular dysfunction[6][11][27][31]. In the eye, galactitol accumulation in the lens fiber cells is responsible for cataract formation, a consequence that occurs even in milder forms of galactosemia such as Type II (GALK1 deficiency)[3][6][27][30]. The osmotic stress induced by galactitol triggers a cascade of cellular responses, including increased intralenticular production of basic fibroblast growth factor (bFGF) and transforming growth factor-beta (TGF-β), altered cytotoxic signaling, and activation of apoptotic pathways[27].

The second major toxic metabolite is galactose-1-phosphate (Gal-1-P), which accumulates upstream of the GALT enzyme block[1][3][6][9][13][31]. Gal-1-P is considered one of the key pathogenic agents in classic galactosemia, with toxicity ascribed to the inhibition of critical enzymes including uridine diphosphate-glucose pyrophosphorylase (UGP), phosphoglucomutase, glycogen phosphorylase, and inositol monophosphatase[9][11][13][31]. However, convincing evidence remains lacking for phosphoglucomutase inhibition in plants, suggesting that the mechanisms of Gal-1-P toxicity may be more complex and cell-type specific than previously appreciated[56]. Notably, GALK1 deficiency, which causes accumulation of metabolites upstream of GALT but not Gal-1-P itself, does not result in the severe brain and ovarian complications seen in classic galactosemia, indicating that Gal-1-P is likely the critical toxic intermediate for these specific manifestations[13][31]. The precise mechanism by which Gal-1-P causes tissue damage remains incompletely understood but appears to involve multiple convergent pathways including metabolic inhibition, aberrant protein modification, cellular stress responses, and signaling pathway dysregulation.

The third significant toxic metabolite is galactonate (D-galactonic acid), produced through oxidation of galactose by galactose dehydrogenase[11][13][31][38]. Galactonate accumulates in various tissues and may contribute to disease pathology through mechanisms including aberrant glycosylation and disruption of normal protein and lipid synthesis[11][13][31][38]. Additionally, under conditions of severe GALT deficiency, accumulated galactose-1-phosphate can activate the pyrophosphorylase pathway, wherein UDP-glucose pyrophosphorylase (UGP) catalyzes the conversion of accumulated Gal-1-P and UTP to form UDP-galactose[1][13][31][38]. While this alternative pathway provides some capacity for metabolite detoxification, the resulting UDP-galactose-dependent reactions are less efficient than the normal Leloir pathway, leading to persistent metabolite accumulation and pathway dysregulation[13][31][38]. The combined effect of these toxic metabolite accumulations triggers multiple downstream pathophysiological cascades that collectively drive tissue damage and clinical disease.

Aberrant Glycosylation as a Central Disease Mechanism

Aberrant glycosylation has emerged as a major mechanism of disease in galactosemia, operating through multiple interconnected pathways that fundamentally disrupt protein and lipid modification[11][13][26][31][38][39]. UDP-hexoses, particularly UDP-galactose and UDP-glucose, serve as essential sugar donors for glycosylation reactions that modify proteins and lipids at multiple stages including posttranslational modification[11][13][26][31][38]. In classic galactosemia, the deficiency of UDP-galactose and the disturbance of the UDP-glucose/UDP-galactose ratio have been directly demonstrated in patient samples[11][13][26][31][38]. Furthermore, accumulated Gal-1-P may directly compete as a substrate for other nucleotide sugar reactions, further depleting the pool of activated UDP-hexose sugars available for glycosylation[11][13][26][31][38]. Studies examining N-glycosylation patterns in galactosemia patients have demonstrated an increase in non-galactosylated (G0) and monogalactosylated (G1) structures alongside decreased digalactosylated (G2) structures, indicating continued N-glycan processing defects despite dietary treatment[26].

The consequences of impaired glycosylation are profound and extend throughout the body, with particular vulnerability in tissues that are rich in complex glycoproteins and glycolipids[11][13][26][31][38][39]. Myelin represents a particularly vulnerable tissue, as it is rich in galactocerebrosides, and autopsy examination of untreated galactosemia patients revealed aberrant glycosylation of galactocerebrosides[11][13][31][39]. The glycosylation of proteins at the neuromuscular junction also plays critical roles in synapse development and function, with studies in Drosophila models demonstrating that GALT deficiency results in overelaborated synaptic architecture and reduced synaptomatrix glycosylation[11][13][31][39]. Polymorphic glycan modifier genes including MGAT3, FUT8, and ALG9 can influence glycan chain bisecting and fucosylation, subsequently affecting cell signaling and adhesion, potentially explaining some of the phenotypic variability observed among galactosemia patients[13][31][39].

The therapeutic relevance of aberrant glycosylation is underscored by studies in other metabolic disorders such as phosphoglucomutase 1 (PGM1) congenital disorder of glycosylation (CDG), where treatment with a combination of D-galactose and complex carbohydrate supplementation improved serum transferrin hypoglycosylation and ameliorated clinical symptoms, suggesting that increased levels of activated UDP-galactose can improve glycosylation[26]. This observation raises the intriguing possibility that selective supplementation of UDP-galactose or its precursors might ameliorate glycosylation defects in galactosemia patients, representing a potential therapeutic avenue that differs fundamentally from the current galactose restriction paradigm[26][38].

Myo-Inositol Deficiency and Signaling Pathway Dysfunction

Myo-inositol deficiency represents one of the most consistently documented biochemical abnormalities in classic galactosemia, having been first reported in post-mortem examination of galactosemia patient brain tissue dating back to the 1960s[11][13][31][39][54]. Myo-inositol serves dual critical roles in human physiology: it functions as a precursor of membrane phospholipids that are essential for calcium and protein kinase C signaling, and simultaneously serves as a buffer of osmotic balance[11][13][31][39]. Brain myo-inositol content peaks prenatally and continues to decline until a postnatal baseline is reached, which is maintained until a secondary decline occurs at middle age, suggesting that myo-inositol availability is particularly critical during early brain development[11][13][31][39].

The mechanisms underlying myo-inositol depletion in galactosemia are multifactorial and involve both reduced production and impaired transport[11][13][17][31][39][54]. High levels of accumulated Gal-1-P may sequester myo-inositol as inositol monophosphate through inhibition of inositol monophosphatase (IMPase), the enzyme responsible for converting L-myo-inositol-1-phosphate to free myo-inositol, thereby limiting intracellular myo-inositol concentration[11][13][17][31][39][54]. Additionally, accumulated galactitol may impair the transcription or function of the SMIT1 myo-inositol cotransporter, reducing cellular uptake of extracellular myo-inositol and further decreasing intracellular availability[11][13][17][31][39][54]. The consequences of myo-inositol deficiency are profound and multifaceted, affecting intracellular signaling through multiple mechanisms.

Recent multiparametric MRI studies have provided direct evidence of persistent myo-inositol deficiency in treated adult galactosemia patients, with significantly lower myo-inositol concentrations detected in the cerebellum, putamen, and cerebral white matter despite lifelong adherence to galactose-restricted diets[14]. The reduction in intracellular myo-inositol has been associated with impaired integrated stress response signaling and endoplasmic reticulum (ER) stress[11][13][31][39][54]. Myo-inositol depletion leads to altered inositide signaling, which can impair calcium homeostasis and trigger ER stress, pathways that are associated with apoptosis and downregulation of phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt) signaling[11][13][17][31][39][54]. This latter pathway is particularly relevant to ovarian dysfunction in female galactosemia patients, as PI3K/Akt signaling is critical for primordial follicle development and oocyte survival[11][13][31][54].

The therapeutic potential of myo-inositol supplementation has been demonstrated in animal models, where myo-inositol supplementation showed positive effects on gonadal and brain damage[54]. Moreover, administration of purple sweet potato color (PSPC) and myo-inositol, compounds hypothesized to rescue aberrant signaling pathways in classic galactosemia partly through their antioxidant properties, ameliorated dysregulation of cellular pathways in experimental models[17]. These findings suggest that myo-inositol supplementation represents a promising therapeutic approach that could potentially complement dietary management and address a pathophysiological mechanism that persists despite galactose restriction.

Endoplasmic Reticulum Stress and Unfolded Protein Response

Endoplasmic reticulum (ER) stress represents a significant and recently appreciated component of galactosemia pathophysiology, with evidence suggesting that accumulation of toxic metabolites, particularly Gal-1-P and potentially aberrantly glycosylated proteins, triggers the unfolded protein response (UPR) as a protective cellular adaptation[11][13][17][28][31][39]. Studies in yeast models of classic galactosemia have demonstrated that the UPR is activated in a galactose-dependent manner and that this protective response is essential for cellular survival under galactosemic conditions[28]. Galactose-1-phosphate synthesis, rather than galactose exposure per se, appears essential for triggering ER stress and subsequent UPR activation, as deletion of the galactokinase-encoding gene completely abolished UPR activation[28].

The molecular mechanisms by which galactose-1-phosphate induces ER stress remain incompletely understood but likely involve multiple convergent pathways[11][13][17][28][31][39]. One hypothesis proposes that ER stress results from defects in protein glycosylation, as the disturbance in UDP-hexose balance directly compromises the capacity for proper N- and O-linked glycosylation of proteins in the ER lumen[13][17][28][31][39]. A second hypothesis suggests that ER stress arises from defects in inositol metabolism and subsequent impaired calcium homeostasis, as Gal-1-P can function as an alternative substrate for inositol monophosphatases, and reduced free inositol availability compromises normal phospholipid signaling necessary for calcium homeostasis[13][17][28][31][39]. The UPR itself, while initially protective, can become pathological if chronically activated, potentially contributing to the long-term neurological complications observed in treated galactosemia patients[11][13][31][39]. Indeed, impairment of the UPR pathway in cellular models makes cells even more sensitive to galactose toxicity, unmasking the cytotoxic effects of the accumulated metabolites[28].

Oxidative Stress and Redox Imbalance

Oxidative stress, characterized by an imbalance between the production of reactive oxygen species (ROS) and the capacity of antioxidant defense systems, contributes significantly to galactosemia pathophysiology and appears to be a modifiable risk factor affecting disease severity[11][13][31][36][37]. Studies in multiple model organisms, including Drosophila melanogaster, have demonstrated that GALT-deficient organisms show dramatically increased oxidative stress when exposed to galactose, and that the severity of oxidative stress correlates with acute toxicity outcomes[36]. Paradoxically, despite heightened oxidative stress biomarkers, galactose-treated organisms also demonstrate lower than expected antioxidant enzyme activities, suggesting that the normal oxidative stress defense mechanisms are compromised under galactosemic conditions[36]. The mechanisms underlying this paradoxical reduction in antioxidant enzyme activity despite elevated oxidative stress have not yet been fully elucidated[36].

The sources of ROS generation in galactosemia appear to be multifactorial, involving both mitochondrial and non-mitochondrial pathways[11][13][31][33][37]. Mitochondrial oxidative metabolism of accumulated galactose metabolites leads to generation of ROS through mitochondrial respiratory chain enzymes[11][13][31][33][37]. Additionally, galactose exposure activates multiple biochemical pathways that generate ROS, including the polyol pathway (which depletes NADPH and compromises antioxidant defense), formation of advanced glycation end products (AGEs), activation of protein kinase C, and the hexosamine pathway[33][37]. The impairment of mitochondrial oxidative phosphorylation efficiency under galactosemic conditions, characterized by declined transmembrane potential and decreased ATP production, further exacerbates ROS accumulation[33][37].

Galactitol accumulation represents a particularly important source of oxidative stress in the lens and other tissues, as galactitol accumulation depletes NADPH levels, leading to decreased glutathione reductase activity and accumulation of free radicals[11][31][50]. The consequences extend beyond simple oxidative damage to DNA and proteins, as oxidative stress modulates gene expression through activation of transcription factors such as NF-κB and AP-1, leading to enhanced expression of pro-inflammatory cytokines[33][37]. AGEs can trigger cell damage through three main mechanisms: accumulation in the extracellular matrix initiating a crosslinking process that reduces connective tissue elasticity; glycated modifications of intracellular proteins impairing cellular function; and binding of AGEs to the receptor for AGE (RAGE) causing activation of inflammatory signaling pathways and apoptosis[33][37]. Importantly, experimental studies have demonstrated that dietary antioxidants including vitamin C and α-mangostin provide protective effects against galactose sensitivity in GALT-deficient organisms, suggesting that antioxidant therapy represents a potentially efficacious therapeutic approach[36][54].

Structural Protein Damage and Enzyme Dysfunction

The fundamental biochemical cause of classic galactosemia involves a severe decrease in enzymatic activity of GALT, with residual activity typically falling below 1 percent in affected individuals[11][16][31][43]. Beyond simple loss of catalytic activity, pathogenic variants of GALT result in structural impairments that compromise protein stability, folding, and cellular localization[1][11][16][31][43]. Some pathogenic variants produce less stable proteins that are unable to achieve correct folding and consequently display increased propensity to aggregation and proteolysis[1][16][31]. Computational structural prediction tools have revealed that novel missense variants such as p.A303D replace buried hydrophobic residues with hydrophilic residues, replace buried uncharged residues with charged residues, and disrupt important hydrogen bonding networks, all of which predict destabilizing effects on protein structure[16].

Protein aggregation represents a critical mechanism through which missense variants compromise GALT function[1][11][31]. The most common p.Gln188Arg variant increases the rate of aggregation, particularly in the absence of zinc cofactor, likely due to its reduced ability to form the uridylylated intermediate[1]. Native proteolysis experiments have demonstrated that apo-GALT (lacking the UMP modification) shows more degradation products than UMP-GALT, and differential scanning fluorimetry reveals a two-phase unfolding curve for apo-GALT with distinct melting temperatures[1]. These findings demonstrate that uridylylation has profound effects on protein stability independent of direct catalytic activity, suggesting that the covalent modification represents a critical structural feature of the enzyme.

The cellular consequences of GALT structural impairment extend beyond simple loss of enzymatic activity to encompass activation of cellular stress response pathways. Cells expressing structurally impaired GALT variants manifest manifestations of ER stress and unfolded protein response activation, suggesting that the misfolded GALT protein itself triggers cellular danger signals[11][28][31][39]. Additionally, accumulation of misfolded GALT protein may trigger autophagy and protein degradation pathways, further reducing the cellular pool of even partially functional enzyme[11][31][39]. Understanding these structural mechanisms has important implications for therapeutic development, as pharmacological chaperones designed to stabilize specific GALT variants and improve their folding, trafficking, and stability represent a promising genetic variant-specific treatment approach[1][11][51][54].

Tissue-Specific Pathophysiology: Central Nervous System Involvement

The central nervous system (CNS) represents one of the most severely affected tissue systems in classic galactosemia, with neurological complications occurring in approximately 85 percent of treated patients despite early diagnosis and dietary intervention[8][11][31][34]. The spectrum of CNS involvement is remarkably broad, encompassing cognitive impairment, motor speech disorders, motor coordination deficits, behavioral and psychiatric complications, and structural brain abnormalities visible on neuroimaging[8][11][31][34]. A critical unsolved question in galactosemia research concerns whether CNS involvement represents progressive neurodegeneration caused by long-term exposure to endogenously produced galactose, whether it reflects developmental abnormalities initiated in utero, or whether the pathophysiology involves a combination of these mechanisms[8][11][31].

Recent neuroimaging studies using optical coherence tomography (OCT) to assess retinal neuroaxonal degeneration as a surrogate marker of brain pathology have provided evidence that CNS involvement in treated classic galactosemia is not primarily a progressive neurodegenerative process[8]. The peripapillary retinal nerve fiber layer thickness was within the normal range for all galactosemia patients studied, and there was no significant effect of disease status or duration on retinal neuroaxonal degeneration markers[8]. These findings suggest that brain damage is more likely to occur early in brain development, potentially in utero or during the neonatal period when galactose levels are extremely elevated[8][11][31]. Supporting this developmental hypothesis, disruptions of fiber tracts and brain nuclei formed during embryogenesis and early fetal brain development have been demonstrated in adult galactosemia patients, indicating that the fundamental CNS injury occurs during critical developmental windows[11][31][39].

The mechanism of early CNS injury appears multifactorial and involves several convergent pathophysiological processes. Galactitol is poorly diffusible and highly osmotic, and elevated brain galactitol in neonates with galactosemia has been associated with diffuse white matter abnormalities and cytotoxic edema[11][31]. In vivo elevation of brain galactitol was associated with diffuse white matter abnormalities in a newborn with classic galactosemia and encephalopathy, demonstrating the direct toxic effects of metabolite accumulation during the critical neonatal period[31]. Additionally, the myo-inositol deficiency documented extensively in galactosemia patients compromises calcium signaling and osmotic buffering capacity, potentially exacerbating metabolite toxicity during the sensitive developmental period[11][14][31][39]. The aberrant glycosylation of proteins and lipids critical for myelin formation and maintenance may further impair CNS development, particularly affecting white matter integrity[11][31][39].

Structural neuroimaging studies have revealed consistent abnormalities in galactosemia patients, including reduced white matter volume and impaired microstructure throughout the brain, with particular vulnerability in the corticospinal tract, cerebellum, bilateral putamen, and superior temporal sulcus[11][31][39]. These regions are highly relevant to the clinical manifestations observed in galactosemia patients, as the cerebellum and basal ganglia are essential for motor coordination and movement control, the corticospinal tract mediates motor commands, and the superior temporal sulcus participates in speech processing[11][31][39]. Abnormalities in cerebral blood flow have also been documented, with elevated cerebral blood flow in emotion-processing regions including the bilateral amygdala and thalamus in treated galactosemia patients, potentially contributing to anxiety and emotional dysregulation[14].

Speech and language disorders represent one of the most prevalent neurological manifestations of galactosemia, affecting the majority of patients[31][32]. Children with galactosemia demonstrate a high prevalence of motor speech disorders classified into three subtypes: childhood apraxia of speech (CAS), dysarthria, and motor speech disorder-not otherwise specified (MSD-NOS)[32]. Among children with galactosemia, approximately 66 percent exhibited significant coordination disorders primarily affecting balance and manual dexterity, and all galactosemia children showed evidence of neurological origin for their speech disorder[32]. The high co-occurrence of speech, coordination, and strength disorders suggests a common underlying etiology, likely associated with diffuse cerebellar and basal ganglia damage[32]. The finding that tongue strength is reduced in galactosemia children, combined with evidence of motor planning deficits characteristic of apraxia, indicates that multiple levels of the motor system are affected, from central motor planning through neuromuscular execution[32].

Tissue-Specific Pathophysiology: Ocular System and Cataract Formation

Cataract formation represents one of the earliest and most characteristic manifestations of galactosemia, occurring in the neonatal period in many patients and representing a direct consequence of galactitol accumulation in the lens[3][6][27][30]. The lens represents a particularly vulnerable tissue because it possesses elevated concentrations of aldose reductase at the anterior side, facilitating galactitol accumulation[3]. Galactitol is osmotically active and poorly metabolized, leading to accumulation within lens fiber cells, where it generates osmotic stress that causes lens swelling, cell lysis, and ultimately cataract formation[3][27][30]. The cataract phenotype differs significantly among the galactosemia types: Type I (GALT deficiency) patients develop cataracts in up to 75 percent of cases within the neonatal period, Type II (GALK1 deficiency) patients almost universally develop cataracts as their primary manifestation, while Type III peripheral form patients do not typically develop cataracts[3][6][42].

The molecular mechanism of cataract formation extends beyond simple osmotic stress to encompass activation of complex cellular signaling pathways[27][30]. Osmotic stress induced by galactitol accumulation triggers increased intralenticular production of basic fibroblast growth factor (bFGF) and transforming growth factor-beta (TGF-β), which initiate altered cytotoxic signaling and activation of apoptotic pathways[27]. Culturing rat lenses in osmotically compensated media containing high concentrations of galactose did not lead to increased growth factor expression or altered signaling unless osmotic stress was present, indicating that the osmotic effect rather than direct galactose toxicity drives the signaling changes[27]. The altered signaling involves activation of mitogen-activated protein kinase cascades including Raf-MEK-ERK and phosphatidylinositol-3-kinase-Akt pathways, and these signaling changes can be normalized by aldose reductase inhibitors through prevention of osmotic stress[27].

At the cellular level, lens epithelial cells exposed to galactose exhibit marked osmotic expansion with appearance of tiny vacuoles around the nucleus in the cytoplasm[30]. This osmotic expansion is mediated by upregulation of chloride channel 3 (Clcn3), a volume-sensitive channel participating in cell volume regulation, and its modulator P-glycoprotein (P-gp)[30]. In galactosemic lens cells, aldose reductase becomes overactivated, generating galactitol and provoking osmotic stress, which leads to marked upregulations of both P-gp and Clcn3, resulting in obvious osmotic expansion[30]. These cellular mechanisms represent potential therapeutic targets, as inhibition of aldose reductase activity prevents osmotic stress and downstream pathological signaling, suggesting that aldose reductase inhibitors represent a rational therapeutic approach for cataract prevention in galactosemia[27][30].

Tissue-Specific Pathophysiology: Hepatic System

The liver represents an acute target organ in galactosemia, with profound pathological changes occurring during the neonatal period in untreated or inadequately treated patients[3][6][7][10][20][42]. The pathophysiology of hepatic injury in galactosemia involves multiple mechanisms including direct toxicity of accumulated metabolites, oxidative stress, ER stress, inflammatory pathway activation, and mitochondrial dysfunction[11][13][31][38]. Galactose-1-phosphate is particularly toxic to hepatocytes and other cells in the body, causing hepatomegaly, liver dysfunction manifested as hyperbilirubinemia, and progressive hepatic failure[20][38]. Histological examination of liver tissue from severely affected neonates reveals mixed-droplet fatty changes, cholestasis with ductular proliferations, hepatocyte necrosis, and collapse of reticular fiber structures[7][20]. Within a period of 3 to 6 months of untreated disease, micronodular cirrhosis develops, followed by ascites and expanding hepatic dysfunction[7][20].

Remarkably, the hepatic pathology demonstrates substantial reversibility with early dietary intervention, underscoring the importance of prompt diagnosis and treatment initiation[19]. A landmark study documented complete reversal of extensive liver damage and cirrhosis through dietary galactose restriction, with liver biopsies obtained prior to treatment showing extensive periportal and intralobular fibrosis, ductular dysplasia, pseudoglandular transformation, and distortion of periportal vasculature[19]. After three months of galactose-free diet, clinical and biological evidence of liver disease disappeared, and follow-up biopsy at five months of age showed normal hepatic histology[19]. This dramatic reversibility indicates that the hepatic injury in the neonatal period is not due to irreversible structural malformation but rather represents acute metabolic dysfunction that can be rescued by removing the offending metabolites[19].

The liver dysfunction has been proposed to be responsible for hypoglycemia through impaired gluconeogenesis, which results from the accumulation of galactose-1-phosphate consuming available phosphate and reducing ATP levels[20][38]. Additionally, Kupffer cells, the liver-resident macrophages responsible for bacterial clearance and immune defense, appear to be functionally impaired in galactosemia, potentially explaining the striking association between galactosemia and Escherichia coli sepsis[21][24]. Multiple studies have documented an association between galactosemia and E. coli sepsis in the neonatal period, with high-risk patients requiring early antibiotic therapy despite the absence of clinical signs or symptoms of sepsis[21][24][55]. The mechanism underlying this increased susceptibility appears to involve hepatic phagocytic dysfunction, as accumulated galactose metabolites may impair Kupffer cell function, compromising the liver's ability to clear bacteria from the portal circulation[21][24][55].

Tissue-Specific Pathophysiology: Renal System

The kidneys represent an overlooked but significant target organ in classic galactosemia, with renal manifestations including renal tubular dysfunction, aminoaciduria, proteinuria, and galactosuria[3][20][38][42]. Renal tubular dysfunction in galactosemia manifests as a pattern characteristic of Fanconi syndrome, with generalized aminoaciduria, phosphaturia, and metabolic acidosis[20][38]. The deposits of galactose-1-phosphate in the proximal renal tubular cells lead to the development of Fanconi-like syndrome through mechanisms that likely involve direct metabolite toxicity and cellular dysfunction[20][38]. A novel complication previously undocumented in the galactosemia population involves development of renal calculi in nonambulatory patients dependent on soy-based formula[23]. Analysis of urinary stone risk factors revealed elevated urine oxalate levels, with stone composition analysis confirming calcium oxalate composition[23]. The underlying mechanism appears to involve decreased mineralization of bone in immobile patients, leading to increased urinary excretion of calcium, combined with low volume intake characteristic of gastric tube feeding plans[23]. This case highlights the need for careful monitoring of urinary oxalate and urine composition in galactosemia patients, particularly those with limited mobility or specialized nutritional support[23].

Tissue-Specific Pathophysiology: Reproductive System and Ovarian Insufficiency

Primary or premature ovarian insufficiency (POI) represents the most common long-term complication in female galactosemia patients, affecting more than 80 to 90 percent of affected individuals despite neonatal diagnosis and careful lifelong dietary restriction[15][31][42][44]. The clinical manifestations of ovarian insufficiency range from primary amenorrhea to secondary amenorrhea or oligomenorrhea, with elevated follicle-stimulating hormone (FSH) levels indicating loss of ovarian reserve[10][15][31][44]. This is in striking contrast to male galactosemia patients, who typically do not exhibit abnormalities in gonadal function[10][15][42]. The complexity and severity of galactosemia-associated POI is underscored by its remarkably poor response to dietary management; the failure of galactose restriction to improve reproductive outcomes suggests that GALT deficiency affects ovarian tissue during the prenatal period, prior to diagnosis and intervention[15][44].

The timing of ovarian damage in galactosemia has been difficult to establish, but multiple lines of evidence support a prenatal or early postnatal origin. Animal studies have demonstrated that prenatal exposure to high levels of galactose interferes with the migration of primordial germ cells to the developing gonad in wild-type rats, reducing the initial oocyte pool[15][44]. Galactosemic fetuses are undoubtedly exposed to extremely high levels of galactose metabolites in utero, as galactose, galactitol, and Gal-1-P levels have all been detected at abnormally high concentrations in fetal tissues[15][44]. This accumulation in utero is most likely due to self-intoxication from de novo galactose synthesis, as galactose is produced from lysosomal hydrolysis of glycoproteins and glycolipids[11][31][44]. The cumulative evidence suggests that the ovaries of galactosemic girls are already functionally different in neonatal life, with possible toxicity initiating in fetal life, resulting in fewer follicles at birth and subsequent accelerated depletion of the follicle pool throughout the reproductive years[15][44].

The molecular mechanisms underlying ovarian dysfunction in galactosemia remain incompletely understood but likely involve multiple pathways[11][15][31][44][54]. Direct ovarian damage could occur through several routes, including increased apoptosis of oocytes and ovarian stromal cells due to accumulated galactose metabolites, accumulation of galactitol generating osmotic stress and cellular swelling, mitochondrial dysfunction, enhanced ROS production and oxidative damage, and defective glycosylation of ovarian proteins[11][15][31][44][54]. An alternative proposed mechanism involves aberrant glycosylation, as disturbance of protein and lipid glycosylation could impair normal ovarian function, either directly through modified ovarian proteins or indirectly through altered signaling[11][15][26][31][44]. Epigenetic mechanisms have also been proposed, with prenatal or neonatal disturbance of the expression of genes involved in follicle development potentially contributing to altered oocyte development[15][44]. Notably, in a mouse model of galactosemia, supplementation with myo-inositol provided protective effects on ovarian function, suggesting that myo-inositol deficiency contributes to ovarian pathology[54]. Additionally, salubrinal, an ER stress reducer that downregulates the PI3K/Akt pathway, showed protective effects on primordial follicle loss and increased fertility in experimental models[51].

Disease Progression and the Temporal Dynamics of Injury

The temporal evolution of galactosemia pathophysiology reveals distinct phases of disease development, with acute neonatal manifestations and long-term complications reflecting different pathophysiological mechanisms and tissue vulnerabilities. In the acute neonatal phase, typically occurring within the first few days to weeks of life when exposed to lactose-containing breast milk or infant formula, galactosemia manifests with striking clinical deterioration including failure to thrive, poor feeding, vomiting, diarrhea, lethargy or coma, hypotonia, bulging anterior fontanella, jaundice, hepatomegaly, and cataracts[3][6][7][10][42][55]. The severity of acute neonatal manifestations correlates with the degree of GALT enzyme deficiency and the levels of accumulated toxic metabolites[43][44][55]. Newborn screening has proven remarkably effective in identifying affected individuals, allowing dietary intervention before maximal accumulation of toxic metabolites occurs[44][55].

The remarkable responsiveness of acute neonatal symptoms to dietary galactose restriction provides compelling evidence for the reversibility of the acute toxic phase. If a lactose-restricted diet is provided during the first ten days of life, the neonatal signs typically quickly resolve[58]. Liver dysfunction and jaundice resolve, hepatomegaly improves, and laboratory abnormalities including elevated transaminases, compromised liver function tests, and metabolic acidosis normalize[20]. Cataracts that develop during the neonatal period in some patients show regression in approximately 55 percent of cases when dietary management is initiated promptly[44]. Renal function, compromised in the acute phase with aminoaciduria and galactosuria, improves with galactose restriction[20][44]. The dramatic reversibility of acute manifestations indicates that the neonatal complications result from acute metabolic dysfunction rather than irreversible structural or developmental damage.

In contrast to the reversibility of acute neonatal manifestations, the long-term complications that develop despite dietary treatment represent the most challenging aspect of galactosemia management[11][31][34][44]. Approximately 85 percent of treated patients develop CNS complications despite early diagnosis and strict adherence to dietary restrictions[8][11][31]. The persistence of these complications despite dietary management strongly suggests that they result from damage that occurs before diagnosis and initiation of treatment, during the critical prenatal and early neonatal periods when metabolite levels are maximally elevated[8][11][31][44]. Supporting this hypothesis, early initiation of dietary treatment within the first week of life is associated with more favorable neurological outcomes compared to delayed treatment initiation[44]. However, the marked variability in neurological outcome even among patients with identical genotypes and comparable treatment timing indicates that additional factors beyond metabolite accumulation drive the phenotypic variability[8][11][31][44].

Current Diagnostic Approaches and Biochemical Assessment

The diagnosis of classic galactosemia relies on the detection of elevated total galactose levels and reduced GALT enzyme activity through newborn screening programs, with confirmation through measurement of erythrocyte galactose-1-phosphate levels, GALT enzyme activity, and genetic testing for mutations in the GALT gene[2][45][49]. Newborn screening programs utilizing dried blood spots obtained in the first few days of life have proven highly effective in identifying affected individuals before symptom onset, allowing intervention that dramatically reduces acute neonatal morbidity and mortality[44][45][49]. The GALT activity assay determines enzymatic activity through semiquantitative spectrophotometric detection of NADH or NADPH produced through sequential enzymatic reactions catalyzed by phosphoglucomutase-1, glucose-6-phosphate dehydrogenase, and 6-phosphogluconate dehydrogenase[45][49].

The classification of galactosemia severity is based on residual GALT enzyme activity, with three distinct categories recognized[16][43][46]. Classic galactosemia is characterized by the absence or near-complete absence of GALT activity in erythrocytes and liver, typically less than 1 percent residual activity[16][43][46]. Clinical variant galactosemia is associated with a drastic reduction in GALT activity, retaining 1 to 10 percent residual activity in erythrocytes and/or liver[16][43][46]. Biochemical variant galactosemia shows 15 to 33 percent residual GALT activity in erythrocytes, which correlates with substantially milder clinical phenotypes[16][43][46]. The Duarte variant, characterized by the N314D mutation, represents a special category with partial enzyme impairment, typically retaining 5 to 20 percent of normal activity and associated with much milder signs and symptoms[2][6][42]. Notably, individuals with biochemical variant galactosemia (10-15% residual activity) do not develop clinical disease, suggesting that restoration of GALT activity to even modest levels (10-15%) would likely rescue the phenotype in classic galactosemia and represents an important therapeutic target[51].

Molecular Heterogeneity and Genotype-Phenotype Correlations

The clinical manifestations of galactosemia exhibit remarkable heterogeneity even among patients harboring identical GALT mutations, suggesting that additional genetic and environmental factors modulate disease severity[8][11][31][44]. The most frequently encountered pathogenic variant, p.Gln188Arg, which accounts for approximately 60 percent of classic galactosemia cases particularly in European populations, demonstrates this genotype-phenotype dissociation by producing variable clinical outcomes in different patients[1][43][44]. The second most common variant, p.Lys285Asn, prevalent in European populations where it accounts for 26 to 34 percent of galactosemia alleles, similarly shows variable expressivity[16][43]. The p.Ser135Leu variant, predominantly found in African American populations, is notably associated with a better prognosis and more frequently manifests as the clinical variant rather than classic form in homozygous individuals[43][46].

The molecular basis for phenotypic variation includes not only the specific pathogenic variants present but also their effects on protein stability, localization, and susceptibility to cellular quality control mechanisms[1][11][16][31]. Variants that primarily affect substrate binding sites result in direct loss of catalytic activity but may preserve protein stability and cellular localization[1]. Variants that disrupt the interface between GALT dimer partners or alter zinc binding sites impair enzyme function through multiple mechanisms[1]. Misfolding variants that reduce protein stability and increase aggregation propensity result in rapid proteolytic degradation, eliminating even partially functional enzyme from cells[1][16]. The identification of modifier genes that influence disease outcome represents an emerging area of investigation, with glycan modifier genes such as MGAT3, FUT8, and ALG9 showing potential roles in modulating disease expression[13][26][31].

Synthesis: The Multifactorial Pathophysiology of Galactosemia

The pathophysiology of galactosemia cannot be attributed to any single molecular mechanism but rather represents the convergent effects of multiple interconnected pathophysiological pathways that are triggered by the absence of functional GALT enzyme. At the most fundamental level, GALT deficiency leads to accumulation of three major toxic metabolites—galactose-1-phosphate, galactitol, and galactonate—which have diverse tissue-specific effects reflecting differences in enzyme expression patterns, metabolic demands, and subcellular localization of metabolite-metabolizing enzymes[11][13][31][38][39]. The accumulation of these metabolites triggers aberrant glycosylation through depletion of UDP-hexose sugars, impairs cellular energy metabolism through metabolite-mediated inhibition of key enzymes, generates oxidative stress through multiple mechanisms, activates ER stress and unfolded protein response pathways, and depletes critical cellular cofactors including myo-inositol[11][13][17][31][38][39].

These primary metabolic disturbances converge on critical cellular signaling pathways that mediate cellular responses to stress, including PI3K/Akt signaling, mitogen-activated protein kinase signaling, and calcium-dependent signaling through phospholipid second messengers[11][13][17][31][39]. Different tissues exhibit striking differences in their vulnerability to these metabolic disturbances, with the developing nervous system, the lens, the ovary, and the liver showing particular susceptibility[11][31][38][39][44]. The timing of exposure to metabolite toxicity critically determines the type of injury that occurs, with prenatal and early neonatal exposure causing developmental abnormalities in the nervous system and ovaries, while postnatal exposure predominantly affects the liver and other organs with high metabolic activity[8][11][31][44]. Despite decades of research and accumulation of substantial knowledge regarding galactosemia pathophysiology, the disease continues to exemplify the complexity inherent in monogenic metabolic disorders, wherein a single enzyme deficiency triggers a cascade of secondary consequences that ultimately determine the clinical phenotype[11][31][38][39].

Conclusion: Current Understanding and Future Directions

Classic galactosemia represents a complex inherited metabolic disorder whose pathophysiology extends far beyond simple substrate accumulation to encompass multiple convergent mechanisms affecting cellular metabolism, protein synthesis, cellular stress responses, and tissue-specific developmental processes. The remarkable dissociation between the excellent outcomes achieved through dietary management of acute neonatal manifestations and the persistent long-term complications observed in the majority of treated patients indicates that our current treatment paradigm, while life-saving, does not adequately address the fundamental pathophysiological mechanisms driving disease. The emerging understanding of disease mechanisms beyond toxic metabolite accumulation, including aberrant glycosylation, myo-inositol deficiency, ER stress, oxidative stress, and signaling pathway dysregulation, has identified multiple therapeutic targets for future intervention[11][31][39][51][54].

Recent advances in nucleic acid therapies, including both mRNA-based approaches utilizing lipid nanoparticles and viral vector-mediated gene therapy with recombinant adeno-associated viruses, have demonstrated proof-of-concept restoration of GALT activity in preclinical models and early clinical studies[51][54]. Pharmacological chaperones designed to stabilize specific GALT variants and improve their cellular trafficking and stability represent a variant-specific therapeutic approach with reduced off-target effects compared to broad-acting inhibitors[1][51][54]. Galactokinase inhibitors aim to reduce accumulation of galactose-1-phosphate by preventing its synthesis, addressing the pathophysiology at an earlier point in the metabolic cascade[38][51][54]. Targeting myo-inositol deficiency through supplementation or through modulation of SMIT1 transporter function offers a mechanism to address impaired signaling and ER stress that persists despite dietary management[11][54]. ER stress reducers and antioxidant therapies address the secondary pathophysiological consequences of metabolite accumulation and may provide synergistic benefit when combined with approaches targeting primary enzyme deficiency[51][54].

The heterogeneity in clinical outcomes even among patients with identical genotypes underscores the importance of personalized medicine approaches in galactosemia management. Understanding the contributions of modifier genes, epigenetic regulation, and environmental factors to disease expression will likely require large-scale prospective cohort studies with comprehensive genetic, biochemical, and clinical characterization[11][31][44]. The persistence of neurological complications despite early treatment raises important questions about the timing and nature of CNS injury, with implications for when preventive interventions should ideally be initiated during development[8][11][31]. Future research elucidating the mechanisms of early developmental injury may identify critical windows of opportunity for intervention that could potentially prevent or substantially ameliorate the long-term complications that currently limit the life quality of galactosemia patients despite access to effective acute treatment. Through continued investigation of disease pathophysiology and rigorous clinical testing of emerging therapeutic approaches, the field of galactosemia research stands poised to transform treatment from the current galactose-restricted diet—which, while life-saving, leaves most patients with persistent complications—toward comprehensive management strategies that address the multifactorial pathophysiology and prevent the long-term sequelae that profoundly affect patient outcomes and quality of life.